Melbourne, Australia and Minneapolis, Minn., Aug. 14, 2017 /PRNewswire/ — Global Kinetics Corporation (GKC), a digital health company revolutionizing the management of Parkinson’s disease, announced today it has recently received Notice of Allowance for U.S. patent application 12/997540, protecting the company’s lead product, the Personal KinetiGraph™ (PKG™) (Parkinson’s Kinetigraph™ outside of the U.S.) system, which the company is marketing in the U.S. The patent application pertains to the objective measurement of bradykinesia. Bradykinesia, or slowness of movement, is one of the most common symptoms, and a defining feature, of Parkinson’s disease. The capacity to continuously measure this movement symptom underpins the PKG system.
Read m ore on PR Newswire here.